Shire Pharmaceuticals has
announced the US$4.2 billion
purchase of ViroPharma, with the
move “entirely consistent with
our clear strategic objective of
strengthening our rare disease
portfolio,” according to Shire ceo
Flemming Ornskov.
ViroPharma products include
Cinryze (C1 esterase inhibitor)
which is approved for the
prophylactic treatment of
hereditary angiodema (HAE), and
will complement Shire’s Firazyr
(icatibant) for the same condition.
ViroPharma’s revenue last year
was US$428m, with Shire saying
it sees “significant opportunity for
future revenue growth” for Cinryze,
both in the US and overseas
markets as new HAE patients are
identified and more doctors gain
experience with the therapy.The above article was sent to subscribers in Pharmacy Daily's issue from 13 Nov 13 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 13 Nov 13
RESPONDING to the findings from the Royal Commission into Aged Care Quality and Safety, a recent government initiative aims to improve medication management in residential aged care facilities by introducing on-site pharmacists.
RESEARCHERS at Charles Darwin University (CDU) are advancing a novel drug delivery system that could potentially eliminate the need for injections to treat various chronic diseases.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.